CARLOS GUSTAVO WAMBIER
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology
- Where
- WAKEFIELD, RI
- NPI
- 1679054043
- Received
- $48,509 in 73 records, 2019 to 2025 ($40,509 general, $8,000 research)
- As principal investigator
- $805,336 of research payments to others in 29 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 19 | $3,806 |
| 2024 | General payment | 19 | $13,127 |
| 2023 | General payment | 23 | $22,306 |
| 2023 | Research payment | 1 | $8,000 |
| 2022 | General payment | 3 | $178 |
| 2021 | General payment | 2 | $79 |
| 2020 | General payment | 2 | $44 |
| 2019 | General payment | 4 | $966 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 32 | $30,383 | 2019–2025 |
| Incyte Corporation | 17 | $8,984 | 2023–2025 |
| Eli Lilly and Company | 1 | $8,000 | 2023 |
| ABBVIE INC. | 7 | $285 | 2020–2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 4 | $213 | 2022–2025 |
| GENZYME CORPORATION | 4 | $209 | 2022–2025 |
| E.R. Squibb & Sons, L.L.C. | 3 | $125 | 2023–2024 |
| Regeneron Pharmaceuticals, Inc. | 1 | $100 | 2025 |
| Galderma Laboratories, L.P. | 1 | $98 | 2019 |
| UCB, Inc. | 2 | $79 | 2021 |
| Allergan, Inc. | 1 | $27 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 7 | $25,625 |
| Consulting Fee | 3 | $10,430 |
| Research payment | 1 | $8,000 |
| Food and Beverage | 50 | $2,502 |
| Travel and Lodging | 11 | $1,852 |
| Education | 1 | $99 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-12 | ABBVIE INC. | $35 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-20 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-18 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-11-03 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-10-30 | Regeneron Pharmaceuticals, Inc. | $100 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-22 | SUN PHARMACEUTICAL INDUSTRIES INC. | $99 | Education | In-kind items and services | 2025 | ||
| 2025-09-26 | Incyte Corporation | $24 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-09-12 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-08 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-07 | PFIZER INC. | $26 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-29 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-17 | GENZYME CORPORATION | $58 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-08 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-06-05 | PFIZER INC. | $770 | Consulting Fee | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-05-20 | SUN PHARMACEUTICAL INDUSTRIES INC. | $43 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-03-08 | GENZYME CORPORATION | $74 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-03-08 | Incyte Corporation | $63 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-03-07 | PFIZER INC. | $61 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-01-21 | PFIZER INC. | $2,310 | Consulting Fee | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | 2025 | |
| 2024-12-13 | GENZYME CORPORATION | $36 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-12-13 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2024 | |
| 2024-12-09 | PFIZER INC. | $4,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | 2024 | |
| 2024-11-26 | Incyte Corporation | $27 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2024 | |
| 2024-09-30 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2024 | |
| 2024-09-16 | E.R. Squibb & Sons, L.L.C. | $24 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2024 | |
| 2024-08-27 | PFIZER INC. | $3 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2024 | |
| 2024-08-05 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2024 | |
| 2024-06-14 | PFIZER INC. | $4,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | 2024 | |
| 2024-04-01 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2024 | |
| 2024-03-25 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2024 | |
| 2024-03-10 | ABBVIE INC. | $40 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-03-08 | PFIZER INC. | $110 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2024 | |
| 2024-03-08 | Incyte Corporation | $88 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2024 | |
| 2024-03-08 | E.R. Squibb & Sons, L.L.C. | $60 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2024 | |
| 2024-03-08 | SUN PHARMACEUTICAL INDUSTRIES INC. | $44 | Food and Beverage | In-kind items and services | Winlevi Drug, Dermatology | 2024 | |
| 2024-02-28 | PFIZER INC. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | 2024 | |
| 2024-02-23 | PFIZER INC. | $26 | Food and Beverage | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2024 | |
| 2024-02-22 | PFIZER INC. | $44 | Travel and Lodging | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2024 | |
| 2023-12-07 | PFIZER INC. | $3,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | 2023 | |
| 2023-11-08 | PFIZER INC. | $32 | Travel and Lodging | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2023 | |
| 2023-11-08 | PFIZER INC. | $3 | Travel and Lodging | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2023 | |
| 2023-11-07 | PFIZER INC. | $3,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | 2023 | |
| 2023-11-01 | PFIZER INC. | $105 | Food and Beverage | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2023 | |
| 2023-10-16 | PFIZER INC. | $3,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | 2023 | |
| 2023-10-11 | PFIZER INC. | $110 | Food and Beverage | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2023 | |
| 2023-09-12 | PFIZER INC. | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | 2023 | |
| 2023-08-25 | Eli Lilly and Company | $8,000 | Research payment | Cash or cash equivalent | TALTZ Drug, Immunology | PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PS | 2023 |
| 2023-08-15 | PFIZER INC. | $135 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2023 | |
| 2023-06-02 | Incyte Corporation | $7,350 | Consulting Fee | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-02 | Incyte Corporation | $226 | Travel and Lodging | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-02 | Incyte Corporation | $82 | Travel and Lodging | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-02 | Incyte Corporation | $50 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-02 | Incyte Corporation | $50 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-02 | Incyte Corporation | $32 | Travel and Lodging | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-02 | Incyte Corporation | $14 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-02 | Incyte Corporation | $14 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-01 | Incyte Corporation | $666 | Travel and Lodging | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-01 | Incyte Corporation | $143 | Travel and Lodging | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-01 | Incyte Corporation | $108 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-01 | Incyte Corporation | $32 | Travel and Lodging | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-06-01 | Incyte Corporation | $8 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-04-27 | E.R. Squibb & Sons, L.L.C. | $40 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2023 | |
| 2022-11-11 | GENZYME CORPORATION | $38 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2022 | |
| 2022-06-15 | SUN PHARMACEUTICAL INDUSTRIES INC. | $25 | Food and Beverage | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2022 | |
| 2022-03-25 | ABBVIE INC. | $114 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2022 | |
| 2021-07-14 | UCB, Inc. | $35 | Food and Beverage | In-kind items and services | Cimzia Drug, Immunology | 2021 | |
| 2021-05-12 | UCB, Inc. | $43 | Food and Beverage | In-kind items and services | Cimzia Drug, Immunology | 2021 | |
| 2020-08-06 | Allergan, Inc. | $27 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-01-31 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2020 | |
| 2019-10-24 | Galderma Laboratories, L.P. | $98 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-04-12 | PFIZER INC. | $311 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-04-12 | PFIZER INC. | $278 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-04-12 | PFIZER INC. | $277 | Food and Beverage | In-kind items and services | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-27 | UCB SA | Rhode Island Hospital | $7,232 | A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in | 2025 |
| 2025-10-10 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $35,825 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2025 |
| 2025-09-26 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $1,509 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2025 |
| 2025-08-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $23,817 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2025 |
| 2025-07-17 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $33,204 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2025 |
| 2025-04-14 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $31,297 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2025 |
| 2025-02-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $48,133 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2025 |
| 2024-10-23 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $32,371 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2024 |
| 2024-10-15 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $38,996 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2024 |
| 2024-07-23 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $42,822 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2024 |
| 2024-07-15 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $24,345 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2024 |
| 2024-06-03 | Eli Lilly and Company | Rhode Island Hospital | $24,500 | PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCAL | 2024 |
| 2024-04-17 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $29,940 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2024 |
| 2024-01-24 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $49,795 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2024 |
| 2024-01-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $20,768 | A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | 2024 |
| 2024-01-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $6,200 | A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | 2024 |
| 2024-01-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | Rhode Island Hospital | $48,863 | A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | 2024 |
| 2023-11-15 | UCB SA | Rhode Island Hospital | $2,708 | A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in | 2023 |
| 2023-11-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | RHODE ISLAND HOSPITAL | $37,340 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2023 |
| 2023-07-14 | SUN PHARMACEUTICAL INDUSTRIES INC. | RHODE ISLAND HOSPITAL | $45,255 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2023 |
| 2023-06-09 | SUN PHARMACEUTICAL INDUSTRIES INC. | RHODE ISLAND HOSPITAL | $3,685 | A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | 2023 |
| 2023-04-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | RHODE ISLAND HOSPITAL | $33,853 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2023 |
| 2023-03-09 | SUN PHARMACEUTICAL INDUSTRIES INC. | RHODE ISLAND HOSPITAL | $10,483 | A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | 2023 |
| 2023-01-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | RHODE ISLAND HOSPITAL | $37,504 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2023 |
| 2023-01-16 | UCB SA | Rhode Island Hospital | $34,942 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZ | 2023 |
| 2022-09-26 | UCB SA | RHODE ISLAND HOSPITAL | $11,209 | A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in | 2022 |
| 2022-07-18 | UCB SA | RHODE ISLAND HOSPITAL | $19,830 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZ | 2022 |
| 2022-01-10 | UCB SA | RHODE ISLAND HOSPITAL | $58,268 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZ | 2022 |
| 2021-07-01 | UCB SA | RHODE ISLAND HOSPITAL | $10,634 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZ | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Wakefield-Peace Dale, RI, county Washington County, RI, state Rhode Island; placed by its city name.
| Measure | Place (city or town) Wakefield-Peace Dale, RI | County Washington County, RI | State Rhode Island |
|---|---|---|---|
| Population B01003 | 9,302 | 130,344 | 1,101,801 |
| Population, 2020 census P1 | 8,925 | 129,839 | 1,097,379 |
| Median age B01002 | 42.8 | 45.5 | 40.6 |
| Under 18 B01001 | 16.0% | 15.4% | 18.8% |
| 65 and over B01001 | 23.6% | 23.3% | 18.7% |
| Households B11001 | 4,179 | 52,549 | 441,570 |
| Foreign born B05002 | 4.5% | 5.0% | 15.3% |
| Median household income B19013 | $106,551 | $106,638 | $87,796 |
| Median family income B19113 | $140,332 | $135,627 | $112,375 |
| Per capita income B19301 | $56,249 | $56,069 | $47,150 |
| Poverty rate B17001 | 9.5% | 8.2% | 11.2% |
| Unemployment rate B23025 | 5.3% | 4.4% | 5.8% |
| Civilian labor force B23025 | 5,232 | 69,349 | 594,253 |
| Mean commute (minutes) B08013 | 24.0 | 26.0 | 25.5 |
| Bachelor's degree or higher B15003 | 59.6% | 52.4% | 37.7% |
| Housing units B25001 | 4,512 | 66,385 | 485,932 |
| Owner-occupied B25003 | 66.3% | 77.5% | 63.6% |
| Renters B25003 | 33.7% | 22.5% | 36.4% |
| Median home value B25077 | $494,400 | $510,800 | $404,200 |
| Median gross rent B25064 | $1,258 | $1,327 | $1,342 |
| White, not Hispanic B03002 | 86.1% | 88.9% | 68.0% |
| Black B03002 | 4.5% | 1.2% | 4.9% |
| Hispanic or Latino B03002 | 3.8% | 3.8% | 17.7% |
| Asian B03002 | 2.2% | 2.1% | 3.5% |
| American Indian and Alaska Native B03002 | 1.5% | 0.3% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Wakefield-Peace Dale, RI.
Comments